Brought to you by 
AC Immune closes $61.4mm IPO on Nasdaq
26 Sep 2016
Executive Summary
Swiss biotech AC Immune SA (radiopharmaceuticals and diagnostics for neurodegenerative diseases) netted $61.4mm in a Nasdaq initial public offering of 6mm shares (upsized from the 4.5mm it had originally planned) at $11 (the low end of its anticipated $11-13 range).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Vaccines
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AC Immune closes $61.4mm IPO on Nasdaq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice